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Summary.-Tumour cells from7 patients with ovarian carcinoma and from22 differ-
ent human tumour xenografts representing a wide range of histological sub-types
have been examined for multicellular spheroid forming ability. Spheroid formation
was limited to cells derived from xenografts. Ofthe22 lines tested, 5 formed spheroids
capable of growth in isolation. There was no clear relationship between histological
type and spheroid-forming ability. The plating efficiency of tumour cells obtained
from spheroids was always greater than for the cells obtained from the dissociated
tumour of origin and was in some cases as much as 6-fold greater. Spheroid growth
was nearly exponential for 4 cell lines.
Volume growth delay was used to investigate the activity of melphalan, adriamycin,
the Vinca alkaloids, CCNU and cisplatin. Differences between lines in drug response
broadly reflected patient and in vivo xenograft response.
THE CHARACTERISTICS of multicellular
spheroids which include intimate cell-to-
cell contact and diffusion gradients for
oxygen, glucose and other nutrients,
makes this a potentially interesting in vitro
model for small solid tumours.
Chinese hamster V79 multicellular
spheroids were first developed by Suther-
land et al. (1971) and subsequently shown
to have a number of properties character-
istic of radiobiological behaviour in vivo,
including the presence ofhypoxic cells and
the ability to re-oxygenate (Durand &
Sutherland, 1976). More recently the
spheroid has been used to investigate
cellular responses to chemotherapy (Yuhas
et al., 1978a; Sutherland et al., 1979;
Twentyman, 1980; Wibe, 1980; West et
al., 1980). It is evident that some of the
characteristics ofspheroids, such as diffus-
ion gradients (Sutherland et al., 1979;
West et al., 1980; Wilson et al., 1981) and
the ability to recover from potentially
lethal damage (PLD) after drug exposure
(Twentyman, 1980) can profoundly influ-
ence chemotherapeutic response.
A simplified method ofspheroid produc-
tion using a static culture technique was
described by Yuhas et al. (1977). Subse-
quently cells from a variety of sources,
including some of human origin, were
shown to form spheroids and to grow in
culture (Yuhas et al., 1978b; Haji-Karim &
Carlsson, 1978; Pourreau-Schneider &
Malaise, 1981). Differences in cell prolifera-
tion kinetics (Yuhas & Li, 1978) and
chemosensitivity response (Yuhas et al.,
1979) between multicellular spheroids of
different origin have been demonstrated.
However, to date there has been no
systematic published study which has
examined the readiness with w%hich cells
from a range of different human tumour
types will form spheroids. In this paper we
report our studies of spheroid formation
using cells derived from 6 different tumour
types. Preliminary data on the response of
spheroids to a range of cytotoxic drugs isHUMAN TUMOUR SPHEROID RESPONSE TO DRUGS
presented and compared with available
clinical and in vivo xenograft drug
responses.
MATERIALS AND METHODS
Clinicalmaterial.-Solidtumourandascitic
fluid was obtained from patients with ovarian
cancer undergoing laparotomy or paracen-
tesis. The tumour was transported to the
laboratory on ice in Hanks' balanced salt
solution. Cells were harvested from ascitic
fluid by centrifugation. Pieces ofsolid tumour
were taken for histology; the remainder was
usedtopreparesingle-cell suspensions.
Xenograft material.-Human tumour xeno-
graftsmaintainedinserialpassageinimmune-
suppressed mice, prepared as described by
Steel et al. (1978), were excised aseptically
from the mouse after cervical dislocation. The
excised tumours were washed twice in PBS at
4°C, representative pieces were taken for
histology and theremainder used to prepare a
single-cell suspension.
Two cell lines derived from metastatic
small-cell lung tumours were established in
vitro (Ellison et al., 1976, and personal
communication). These cells (designated ME/
MAR and ME/FRE), were used at early
passage ( <20 from explantation) to establish
multi-cellular tumour spheroids. Subse-
quently these cells were shown to form
tumours in immune-suppressed mice and to
conform with our xenograft nomenclature
have been called HX123 (ME/FRE) and
HX124 (ME/MAR).
Tumourdisaggregation.-The tumours from
patient or xenograft were washed, finely
choppedandthen incubated infilter-sterilized
collagenase (Sigma Type II) at a concentra-
tion of 2 mg/ml in full medium (Hams F12
(Gibco) +15% Special Bobby Calf Serum
(SBCS) (Gibco) +penicillin 50 u/ml, strepto-
mycin 50 ,Lg/ml and neomycin 10 jg/ml)
for 1 h at 37°C. Ten ml of collagenase
solution were used per gram of tissue. At
the completion of incubation the tumour
fragments and cells were centrifuged, washed
twice in PBS and then exposed to pre-
warmed 0-25% trypsin (Bacto) in PBS for 15
min at 37°C. Trypsin activity was inhibited
by the addition of SBCS to a final concentra-
tion of 15%. Two further washes in PBS with
recentrifugation were carried out, followed
by the addition offull medium. The resulting
suspension was agitatedfor a further2-3 min,
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the large fragments allowed to settle and the
supernatant filtered through a 25,um poly-
ester mesh filter. This procedure produces a
satisfactory single-cell suspension with cell
yields in the range of 1-50x 106 cells/g
depending on the tumour type. Cell clumps of
2-4 cells usually constituted <5% overall cell
number.
Spheroid production.-XVe have used the
method of Yuhas et al. (1977) with some
minor modifications in order to initiate
spheroid growth. Routinely 10 ml of 1% agar
(Agar Noble, Difco) in full medium was used
as a base coat in 9cm bacteriological Petri
dishes (Sterilin). Some tumours did not need
an agar base coat for spheroid formation,
while the melanoma xenografts would not
form spheroids unless the agar base coat was
1-5%, as the cells otherwise penetrated the
agar. The cells were seeded into dishes at a
concentration of1-3 x 106cellsperdish,gassed
with a sterile 5% 02, 5% C02, 90% N2
mixture and incubated at 37°C in sealed
polystyrene boxes. Medium was replenished
twice weekly.
Treatment with cytotoxic agents.-Spheroids
were harvested and sorted into universal
containers, washed and re-suspended in
4-5 ml fresh full medium. An appropriate
amount of drug in 0-5 ml PBS was then
added, and the spheroids incubated for 1 h at
37°C in an atmosphere of5% 02,5% C02 and
90% N2. At the completion of the drug
exposure, treated and control spheroids were
washed twice in PBS and re-suspended in full
medium. Using an Olympus binocular in-
verted microscope fitted with micrometer
eyepieces at 900 to each other, spheroids of a
predetermined size were selected for spheroid
growth or cell-survival studies.
Individual spheroids were then pipetted
into wells of a 24-well Linbro plate (3-5 ml
capacity per well) base coated with 0-5 ml 1%
agar in full medium and overlaid with 1 ml of
the medium and incubated at 37°C in sealed
polystyrene boxes in 5% 02, 5% CO2 and
90% N2. Twelve-24 spheroids were plated
for each drug concentration and 24 untreated
spheroids were used as controls.
Spheroidgrowth was assessedbymeasuring
the maximum diameter of each spheroid and
thediameter at 90° to the maximumandtheir
volumes were then calculated using the
formula for ellipsoids. Each spheroid was
followed individually throughout the experi-
ment and measured at least twice weekly.
871A. C. JONES, I. J. STRATFORD, P. A. WILSON AND M. J. PECKHAIM
Spheroids were dissociated into single cells
by incubation in prewarmed 0 025% trypsin
in PBS for 10 min followed by gentle
pipetting. Cell survival was assessed using a
twin-layer soft-agar method similar to the one
described by Courtenay (1976). The cells
HX70, HX99 and HX34 were plated in
medium containing 15% SBCS; however, the
small-cell tumour lines (ME/MAR and ME/
FRE) required 15% foetal calf serum instead
ofSBCS. The agar overlayer was 0 25% agar,
the underlayer remained at 0.500 made up
with Hams F12 and antibiotics as described
earlier. Washed August rat red blood cells,
treated for 1 h at 44°C, were added to give a
final concentration of 1/40 in the agar
overlayer. In addition, heavily irradiated cells
from dissociated untreated spheroids were
employed in all assays to produce a final
plated cell number of 104 tumour cells/dish.
The plated dishes were incubated at 37°C in
5% 02, 500 C02, 90 N2 for 14-21 days. Cells
givingrise to colonies of > 50 cells were scored
as survivors.
Drug8. Stock solutions of drugs were
made up at a concentration of 1 mg/ml.
Adriamycin (Farmitalia) was dissolved in
sterile distilled water and used fresh or stored
at -20°C for a maximum of 1 month until
used. Subsequent dilutions were made in
PBS. The remaining drugs were all prepared
immediately before use. Melphalan (supplied
by the Drug Synthesis and Development
Branch, NCI) was dissolved in 2% HCI in
ethanol before dilution with PBS.
CCNU (Lundbeck) was dissolved in 20%
ethanol in propanediol and diluted in PBS.
The Vinca alkaloids (Eli Lilly) and cisplatin
(Drug Development and Synthesis Branch,
NCI) were dissolved and subsequently diluted
in preservative-free PBS. Appropriate control
experiments were performed with diluted
solvents and these had no detectable effect on
spheroid growth.
RESULTS
Spheroidformation
As part of a study examining direct
cloning in ovarian cancer, some of the
patient material was used in the attempt
to initiate spheroid formation. Five
patients with adenocarcinoma ofthe ovary
provided untreated solid tumours. Two
patients provided ascitic fluid with many
cell clumps. In our system the cells
obtained from the dissociated tumours all
formed aggregates measuring 150-200 /im
over a period of 7-10 days. The progress of
the aggregates was followed for up to 6
weeks but no further increase in agregate
size was observed. Similarly over 4-5
weeks no change was noticed in the
appearance of the clumps of cells derived
from ascites and no growth occurred.
Table I shows the xenografts that were
studied to determine whether or not
spheroids could be formed from the
dissociated tumour cells. Over a range of
histologically different tumours, aggre-
gation amongst cells occurred; only 3
tumours failed to produce any significant
aggegation. However, of the 19 xenograft
tumours that did produce aggregates only
5 (HX34, HX70, HX99, HX123 and
HX124) appeared able to form spheroids,
which we have defined as aggregates which
were both spherical and capable ofgrowth
in isolation. There was no clear-cut
relationship between spheroid formation,
histological type and ability to produce
colonies in agar.
Table II shows a comparison of the
plating efficiency (PE) (defined as colonies
counted/no. cells plated x 100%) between
cells obtained direct from the tumour and
those cells obtained from dissociated
spheroids. There was a wide variation in
plating efficiencies for cells derived from
the different xenograft tumours, ranging
from 0-530o to 23-4%. For each cell line
(with the exception of ME/FRE/HX123)
the PE of cells derived from the spheroids
was significantly higher than that for the
cells taken directly from the tumours.
Growth ofspheroids
Growth curves for melanoma spheroids
(HX34), lung-adenocarcinoma spheroids
(HX70), breast-carcinoma spheroids
(HX99) and 2 small-cell tumour lines
(HX123 and HX124) are shown in Fig. 1.
Near-exponential growth was seen for the
HX34, HX70, ME/MAR and ME/FRE
spheroids over the size range 0-01-0-1
mm3. Volume-doubling times for these
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TABLE I.-Summary of xenograft tumours examinedfor spheroidformation
Tumour Histology
Ovary
HX62 Adenocarcinoma
HX61 Adenocarcinoma
HX109 Adenocarcinoma
HX110 Adenocarcinoma
HX113 Adenocarcinoma
HX121 Adenocarcinoma
Aggregation in
static plates
150 'um
Ability of
Tumour cells
Growth in to form
individual colonies
wells in agartt
_ +
_ +
_ +
- +
_ +
HX69
HX70
HX72
HX82
HX83
HX94
HX123
HX124
Lung
Small-cell
Adenocarcinoma
Small-cell
Large-cell
Adenocarcinoma
Adenocarcinoma
Small-cell
Small-cell
Breast
HX99 Adenocarcinoma
HX106 Comedocarcinoma
Teratoma
HX39
HX57
HXIl1
HX34
HX47
HX32
+
+
+
+*
+
+
+
+
+
+
+
Melanoma
Gastrointestinal
Pancreatic carcinoma
+
+
+*
+
+
* Loose irregularly growing clumps only.
t Papillary aggregates.
tt PE>0 1%.
spheroids within this size range varied
from 1-7 days for HX34 to 3-5 days for
ME/MAR. HX34 continued growing
exponentially until sizes > 1 mm3 were
reached. None of the other cell types
would form spheroids of this size. The
most slowly growing spheroids were from
the breast carcinoma HX99; they required
12 days to double their volume from 002
to 004 mm.3 In addition, the volume-
doubling time of HX99 spheroids clearly
increased as the spheroid size increased.
The data in Fig. 1 came from a single set of
experiments; growth curves for untreated
spheroids were determined in all drug
treatment experiments (see following fig-
ures) and gave similar curves to those
shown in Fig. 1. Generally, for clarity,
error bars are omitted from figures;
however, statistical analysis was per-
formed on each set of results and stat-
istical differences have been included in
figure legends where differences in
response were observed.
Response to cytotoxic drugs
The effect ofmelphalan on thegrowth of
HX70 spheroids is shown in Fig. 2. In this
and subsequent figures, data are normal-
ized to the initial treatment volume. At
each ofthe doses tested melphalan caused
growth delay. However, the doses required
to delay growth of the lung-adenocar-
cinoma (HX70) spheroids were consider-
ably higher than those found to be
effective against the small-cell carcinoma
(ME/MAR, ME/FRE) spheroids. Fig. 3
shows that doses as low as 05 ,ug/ml
caused growth delay in both small-cell
carcinoma lines. Furthermore, treatment
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TABLE II.-A comparison of plating efficiency (PE) of tumour cells taken direct from
xenograft tumours with cells from dissociated spheroids.
PE xenograft + s.e. aPE spheroids +s.e.
HX99 0 53+0 08 (9) 2-86+0.68 (9)***
HX70 4 -97 + 0 52 (16) 26-79+2-41(13)****
HX34 23 40+1-66 (13) 33-93+3-47 (3)**
(HX124) 2-87+2-B (3) 20-0 +12-5 (3)*
ME/MAR
(HX123)15 7 +10-3 (3) 26-3 +9 7 (2)
ME/FRE
a Cells were taken from spheroids of diameters in the range
200-300 ,um.
Plating efficiencies significantly different, ****P<0*0001;
***P<0.01; **P<0-02; *P<0 1
(Numbers in parentheses indicate number of separate
experiments.)
SPHEROID GROWTH
1
0.1
mE
E
I--
0.01
10
vt/vo
1 o HX 34
o HX 70
f ME/MAR
* ME/FRE
* HX99
30
Time /days
Fig. l.-Growth curves of untreated spheroids
derived from 5 different tumours. (Standard
errors are shown).
of 234,um-diameter ME/MAR spheroids
with 0-1 ,ug/ml melphalan was sufficient
to cause progressive break-up of the
spheroid. This wasduetothelethaleffectof
1I0p,g/mlmelphalanonME/MARspheroids
of this size. Melphalan at a concentration
of 10 ,ug/ml was found to be effective in
causing growth delay (as shown in Fig. 4)
for both melanoma (HX34) and breast
(HX99)-tumour spheroids.
Spheroid growth following exposure to
adriamycin is shown in Figs 5 and 6.
MELPHALAN HX70
Iritial treatment
diameter
183±6pm
conttmi
3pg/ml
Spg/m
l0pgrri
5 10 15 20 25
Time /days
FIG. 2.-(The diameter on this and subse-
quent figures is the mean diameter (tum) of
the plated spheroids +s.e.) The effect of
increasing concentrations of melphalan
after 1 h exposure on the growth ofadeno-
carcinoma of lung-derived spheroids. At
Day 14 the difference between control and
3-0 ug/ml was significant (P<0.001) and
the difference between 3 0 ug/ml and 10 0
,Ag/ml was also highlysignificant (P< 0 001)
(using Student's t-test).
Within the range of achievable peak
plasma levels in man (06 ,ug/ml, Alberts &
Chen, 1980) significant growth delay was
not observed except for the breast-tumour
spheroids (HX99). The lung-adenocar-
cinoma spheroids (HX70) remained un-
responsive even at 5.0 ,ug/ml. Growth
delay has been observed, however, at
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MELPHALAN ADRIAMYCIN
Vt/VO
DAYS
FIG. 3.-Growth curves of2small-cell tumour-
derived spheroids following melphalan
exposure for 1 h. The statistical differ-
ences between control and lowest treated
dose were significant at P<0-01 (ME/
FRE) on Day 13 and P<0-05 (ME/MAR)
on Day 14. A statistical difference was also
found (P< 0-02) between melphalan 0-5
,ug/ml and melphalan 1-5 utg/ml for
ME/FRE, but not observed with ME/
MAR.
MELPHALAN
vt/v0
U 20 U0 20 10 20
DAYS
FIG. 5.-The response of the 3 lung-tumour-
derived spheroids (HX70: adenocarcinoma;
ME/FRE: small-cell; ME/MAR: small-
cell) to increasing concentrations of
adriamycin for 1 h exposure is shown.
No significant difference between control
and treated spheroids was found.
ADRlAMYCN
vt/vo
1U 2U 10 20 30
DAYS
FIG. 4.-Growth curves ofmelanoma (HX34)
and breast (HX99)-derived spheroids
after exposure to melphalan at various
concentrations for 1 h. For HX99 a
statistical difference was observed at Day
13 between control and 1-0 ,ug/ml (P < 0-01)
but not between 1-0 ,ug/ml and 2-0 ug/ml.
For HX34 a statistical difference between
control and 1-0 jug/ml was also observed
(P < 0-01).
higher concentrations of drug than were
used in these experiments with the small-
cell tumours ME/FRE and ME/MAR
(West, Stratford & Jones, in preparation).
The melanoma spheroids (HX34)
appearedunresponsive at clinically achiev-
X0 20 10 20 30
DAYS
FIG. 6.-Melanoma spheroids (HX34) and
breast spheroids (HX99) after exposure
to different concentrations of adriamycin
for 1 h. A statistical difference at Day 12
(P< 0-05) was observed between control
and 1-0 t*g/ml and between 1-0 Zg/ml
and 3-0 ,ug/ml (P<0-001) for HX34.
Similarly a significant difference between
control and 0-5 jug/ml at Day 13 for HX99
was also observed (P <0-02). However, no
significant difference was found between
0-5 jug/ml anid 1-0 ug/ml.
able drug concentrations but did exhibit
growth delay at higher concentrations.
Responses to vindesine and vincristine
are given in Figs 7 and 8. At the
concentrations tested vindesine did not
affect the growth of HX34, HX70 or
ME/FRE. In contrast even the lowest
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VINDESINE
HX70 ME/FRE
100r-
ME/MAR
d=209±14pm
10
o control
o 0O5pg/ml
02
--
* 0 2---
DAYS
FIa. 7.-The response of the lung-tumour-
derived spheroids after exposure to
vindesine for 1 h. Only for ME/MAR was
a statistical difference found between con-
trol and the lowest dose examined (P<
0-01 at Day 13). This statistical difference
was also seen between lowest and highest
doses (P <0-05).
HX34 VINDESINE HX99 VINCRISTINE
Vt/VO
DAYS
FIG. 8.-The lack of response of the mela-
noma (HX34) spheroids when exposed
to even the highest dose of vindesine is
shown (the lower dose points have been
ornitted) in the left panel. In the right
pausel, the response of HX99 (breast)
sptferoids to vincristine exposure for 1 h
is illustrated. There was a statistical
difference between control and 0-1 ,ug/ml
(P<0.001) and between 0-1 ,ug/ml and
0-5 jug/ml (P<0.001) at Day 12.
concentration ofvindesine induced growth
delay in the other small-cell-carcinoma-
derived spheroids ME/MAR. Vincristine
was observed to cause dose-dependent
growth delay in the breast-tumour
spheroids (HX99).
The above results have shown that the
adenocarcinoma spheroids (HX70) are
i1
1
HX70
CCNU
o cortrol
o 1.7pg/ml
A 33--
*50--
d-320±12jum
Vncrtstne
o control
o0 O5pg/rrl
d=267±10,um
10 20 30
DAYS
CisPtatin
control
5Nr
10-
15---
A
d =219±7ym
Vrbbstine
o control
0 1 pg/nt
d=255±17pm
I I -1~~~~~~~~~~~~~~
10 20 30
FIG. 9.-The 4 panels show the response of
the adenocarcinoma lung spheroids to 4
different drugs at different concentrations
following a 1 h exposure. Statistical
differences between control and treated
curves were only seen after exposure to
cisplatin. At Day 13 the difference be-
tween control and 5 0 ,ug/ml was significant
at P <0-001 and between 5-0 ,ug/ml and
15 tcg/ml at P < 0-001.
clearly resistant to melphalan, adriamycin
and vindesine. We have further examined
the sensitivity of this line to vincristine,
vinblastine, CCNU and cisplatin (Fig. 9).
Only cisplatin showed any growth inhibi-
tion, and at 10-0 ,tg/ml this drug caused 13
days' delay in the time taken to reach 4
times the treatment volume.
DISCUSSION
In this study the ability of tumours to
form multicellular spheroids was assessed
using fresh biopsy material from 7 ovarian
carcinoma patients and 22 different
human tumour xenograft lines including
ovarian, lung, breast, testicular and pan-
creatic cancer and malignant melanoma.
Successful spheroid formation, as judged
by the capacity of spheroids to grow in
isolation, was not observed with cells
taken direct from the patient despite
aggregate formation by nearly all the
876
vvviZ I -uHUMAN TUMOUR SPHEROID RESPONSE TO DRUGS
0
4 ~ ~ ~ ~ ~ ~ ~
.0 ~ ~ ~ ~ ~
0 0 o
0 4-i 1-40 .
0~~~~~~~~~~~~0c
00 p 0
4
0 o~~~~~
~ ~ ~
0
0)0( 30 0 0 0"
04' 04. -00 4 g 0P. 00
-0 D
0 0
M
0~~~~~~~~. .5 ;4
0~~~~~
> 0 ~ ~ ~ ~ ~
4 0bO
4 0 W, p0
0
.
> 000
877A. C. JONES, I. J. STRATFORD, P. A. WILSON AND M. J. PECKHAM
xenografts that were examined, only a
limited number went on to exhibit growth
of spheroids from aggregates. As a
capacity for in vitro colony formation has
been demonstrated for most of the xeno-
grafts (Table I), the infrequency of
spheroid formation is interpreted as being
at least partly due to sub-optimal growth
conditions rather than an inherent
inability of the tumours to grow in vitro.
Factors that will increase the ability of
tumour cells in vitro to form spheroids are
under investigation.
The enhanced plating efficiency of cells
derived from spheroids, compared with
those obtained from xenografts (Table II)
may reflect the absence of stromal cells in
spheroids. Histological and immunocyto-
chemical stains have confirmed that
spheroids derived from xenografts in
immune-deprived mice consist only of
human cells (Jones & Wilson, unpub-
lished). However, the absence of stromal
cells is unlikely to explainthesometimes 6-
fold increase in plating efficiency that we
have observed. Spheroid formation may
selectively favour clonogenic tumour cells.
Alternatively, intimate intercellular con-
tact with adequate nutrition may stimu-
late quiescent cells to proliferate.
Experiments are in progress using cell-
sorting techniques to examine the nature
and origin ofthe phenomenon ofincreased
plating efficiency.
The growth curves obtained for the 5
tumour lines (Fig. 1) differ from each
other, but are broadly similar to those that
have been reported for other human lines
grown from spheroids (Byfield et al., 1980;
Haji-Karim & Carlsson, 1978; Pourreau-
Schneider & Malaise, 1981). The growth
fraction of multicellular spheroids has
been shown to be a major determinant of
growth rate (Yuhas & Li, 1978). In our
study a correlation exists between growth
rate and plating efficiency (Fig. 1 and
Table II). The low growth rate observed
with the breast-carcinoma spheroids
(HX99) has previously been reported for
other human-breast-carcinoma spheroids
(Yuhas & Li, 1978).
Most reported studies concerning
spheroids have used cell survival as the
principal end-point. Growth delay has
received less attention but nevertheless
has shown a dose-dependent response to
radiation and drugs (Durand, 1976;
Pourreau-Schneider & Malaise, 1981;
Yuhas et al., 1978a; Twentyman, 1980).
However, there have been no studies in
which growth delay has been used to
identify heterogeneity ofresponseamongst
tumour lines. Our results suggest that
growth delay can identify differences in
drug sensitivity amongst human tumour
lines.
One objective of this study has been to
compare the response of spheroids to
cytotoxic drugs with that of the patient's
tumour. Drug concentrations for spheroid
exposure were therefore based on plasma
concentrations achievable in man (after
Alberts & Chen, 1980). For melphalan,
pharmacokinetic data obtained after i.v.
high-dose administration were also used
(McElwain et al., 1979). It has been
possible to compare the spheroid response
with that observed in the patient in only a
proportion of cases, since not all patients
received chemotherapy (Table III). In
addition, comparison has been further
restricted by the frequent use of drug
combinations to treat patients and the
consequent difficulty of ascribing the
clinical response to a particular drug. As a
result the spheroid response was also
compared with the xenograft tumour
response, particularly as xenografts are
being recognizedincreasingly as exhibiting
a response that reflects that seen in the
patient (Nowak et al., 1978; Shorthouse et
al., 1980).
The responses that have been observed
in our tumour spheroids and the patient
and xenograft responses are summarized
in Table III. The clinically resistant
tumours (HX34 and HX70) were drug-
resistant when treated as spheroids, while
the small-cell tumours (ME/FRE and
ME/MAR) showed a mixed response in
vitro. Concordance between the xenograft
response using growth delay as the end-
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point and the spheroid response was also
seen.
Our data would suggest that spheroid
formation from human tumour material
does not occur with the same frequency
and readiness as spheroid formation from
established in vitro cell lines (Yuhas et al.,
1977). Despite this, we feel that spheroids
derived from arange ofhuman tumours do
merit further attention as an in vitro
tumour model since they appear to show
differences in drug responsiveness in keep-
ing with their tumour oforigin.
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